Hematopoietic stem cell transplantation (HSCT) is an established therapeutic intervention for a variety of haematological malignancies and non-malignant disorders. Central to the success of HSCT is ...

HLA matching in bone marrow transplantation has an important role in determining successful outcome. However HLA typing of both potential related and unrelated donors can be both time-consuming and ...

Biomarker testing and patient demographic disparities among breast cancer patients across treatment settings. Sociodemographic and clinical determinants of survival in metastatic breast cancer: A ...

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Primarily, the transplantation from a ...

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors The study included 17,292 unrelated ...

Jayme Locke, MD MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at ...

(ORLANDO, Dec. 6, 2025) A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, ...

ORLANDO -- Stem-cell transplants with mismatched unrelated donors (MMUDs) beyond a single HLA locus (<7/8) had 1-year survival similar to better-matched donors, suggesting significant potential to ...